New Markets, New Media
Digital Marketing is Dead, Long Live Marketing!
The days of digital marketing as we know it are over. Pharma companies need to step into a new world where branding is more seamlessly integrated across mediums. Digital should be thought of as a delivery mechanism, not a channel. The trick to this new way of marketing is to start with an idea and work ...Read more
Obesity Drug Promotion
Belviq's Battle of the Bulge
Arena Pharmaceuticals' and marketing partner Eisai's Belviq – the first FDA-approved drug to treat obesity in over a decade – is making progress with payers and beefing up sales forces to target primary care physicians. DTC support began in September ...Read more
Meetings & Events
Winning Pharma's Conferences
Like the Super Bowl, pharma companies are winning major congresses by using competitive conference techniques to generate brand buzz and corporate recognition. From year to year, conferences are planned the moment the last one ends all the way from pre-planning to execution to post-run evaluation. Stan Bernard explains that it's not necessarily about how compelling your data are at these conferences, but rather how you showcase it ...Read more
Pharmaceutical Executive editorial staff proudly introduces PharmExec TV, their latest high quality pertinent content in a brand new industry-breaking format. Tune In Now
Commercial Strategy
The Little Orphan That Could: How Alexion is Going Global
How does a small biotech with one drug on the market for rare disease position itself in the global commercial space? Alexion Pharmaceuticals, in its quest for approval and access to markets the world over has chosen to focus on fostering awareness with physicians of the diseases it treats, paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremia syndrome (aHUS). Clark Herman reports ...Read more
New E-Book- Lifecycle Solutions: Positioning Pharmaceuticals For Commercial Success
Time is risk. If time to market is slowed then the cost for a company is lost revenues, profits, and ultimately lost opportunities for patients. The message is clear. To compete and win, companies must wrest more value from every stage of a new product’s tightly projected lifecycle. Download Now
Strategy Overview
Taking Stock: Notes on the Industry Audit
PharmExec Editor-in-Chief Bill Looney summarizes our latest industry audit in defining mid-size companies as the ones to watch. In the midst of regulatory uncertainty, slower growth and formulary control in the hands of few PBMs, the general advice is that companies become and remain nimble operations and realize their power to price effectively ...Read more
|
